News

Mr Lapointe is currently CEO of Sigma-Tau Pharmaceuticals, a company engaged in the development and commercialization of medicines for patients with rare diseases. Sigma-Tau is Dor’s North American

Cook Medical, a provider of medical devices, has reported positive results from an 11-month clinical study on Biodesign, a vaginal erosion repair graft for the treatment of vaginal

For the full year 2008, NPS reported a net loss of $31.8 million, or $0.67 per diluted share, compared to a net loss of $4.28 million, or $0.09

Sopheon has announced that Ciba, a manufacturer of specialty chemicals, has implemented the company’s Accolade product portfolio and innovation process management system to support its global initiative aimed

For the fiscal year ended December 31, 2008, net income totaled $1.83 million, or $0.11 per diluted share, compared to $2.24 million, or $0.13 per diluted share, for

For the 12 months ended December 31, 2008, the company reported a net loss of $13.16 million, or $0.31 per share, compared to a net loss of $41.46

For the year ended December 31, 2008, net loss was $44.7 million, or $1.51 per share, compared to a net loss of $43.7 million, or $1.60 per share,

Roche and Genentech, a biotechnology company, have signed a merger agreement under which Roche will acquire the outstanding publicly held interest in Genentech for $95 per share in

An EUA authorizes the use of unapproved medical products or unapproved uses of approved medical products during a declared public health emergency. “The FDA worked quickly with the